Citations 0
June 7, 2006

High-Dose Statins and the IDEAL Study

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;295(21):2476-2479. doi:10.1001/jama.295.21.2476-b

To the Editor: Dr Pedersen and colleagues1 conclude that while high-dose atorvastatin for secondary prevention of coronary artery disease following acute myocardial infarction produced no statistically significant decrease in all-cause or cardiovascular mortality compared with usual-dose simvastatin, the lack of a difference between the 2 groups in adverse events classified as serious implies that patients with established coronary artery disease may benefit from intensive lipid lowering without serious adverse events.

First Page Preview View Large
First page PDF preview
First page PDF preview